Skip to main content

Published locations for No benefit of adding ibrutinib to chemoimmunotherapy in relapsed/refractory mature B-cell non-Hodgkin lymphoma

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. No benefit of adding ibrutinib to chemoimmunotherapy in relapsed/refractory mature B-cell non-Hodgkin lymphoma

User login

  • Reset your password
  • /content/no-benefit-adding-ibrutinib-chemoimmunotherapy-relapsed/refractory-mature-b-cell-non-hodgkin
  • /hematology-oncology/article/262008/b-cell-lymphoma/no-benefit-adding-ibrutinib-chemoimmunotherapy
  • /breast-cancer-icymi/article/262008/breast-cancer/no-benefit-adding-ibrutinib-chemoimmunotherapy
  • /b-cell-lymphoma-icymi/article/262008/b-cell-lymphoma/no-benefit-adding-ibrutinib-chemoimmunotherapy